|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||752.55 - 787.75|
|52-week range||355.30 - 814.50|
|Beta (5Y monthly)||0.55|
|PE ratio (TTM)||37.85|
|Forward dividend & yield||6.00 (0.79%)|
|1y target est||N/A|
Zydus Cadila on Thursday launched the cheapest generic version of Gilead Sciences' antiviral drug remdesivir in India to treat COVID-19 following reports of shortages at hospitals in the world's third-worst hit nation. Zydus has priced it at 2,800 rupees ($37.44) per 100mg vial. It will be sold under the brand name Remdac to government and private hospitals treating COVID-19 patients, the company said in a regulatory filing https://reut.rs/3gTivT4.
India's supply of antiviral drug remdesivir and generic equivalents is stabilising after shortages of the vital COVID-19 medicine at hospitals, according to a top executive at one of the country's big drugmakers, Cipla Ltd. Remdesivir, made by U.S.-based Gilead Sciences Inc, has been in high demand globally, and a handful of companies including Cipla are authorised to make and sell generic versions in 127 developing nations. Cipla's launch of remdesivir in late June, along with subsequent launches by others, has helped ease supply bottlenecks in India, Cipla's Global Chief Financial Officer, Kedar Upadhye, told Reuters.
Cipla Ltd has received Indian regulatory approval to sell anti-viral drug favipiravir to treat COVID-19, the drugmaker said on Friday, as coronavirus infections in the world's third worst-hit nation show no sign of abating. The Drug Controller General of India granted Cipla accelerated approval to make and sell favipiravir in an effort to meet the "urgent and unmet" need for COVID-19 treatment options in the country, the company said. Indian drugmakers including Glenmark Pharmaceuticals Ltd are racing to supply generic versions of favipiravir, originally developed by Japan's Fujifilm Holdings Corp as Avigan for treating influenza.